



## ASX ANNOUNCEMENT

### Actinogen appoints Professor Paul Rolan as Chief Medical Officer

**Sydney, 15 February 2022. Actinogen Medical ASX: ACW (“ACW” or “the Company”)** is pleased to announce that it has appointed Professor Paul Rolan as Chief Medical Officer (CMO), effective today. Professor Rolan assumes the CMO role from Dr Steven Gourlay who has been Acting CMO since his appointment as CEO in March 2021.

Professor Rolan is a clinical pharmacologist and drug development consultant and one of Australia's most experienced clinical trial investigators and drug developers, having taken drugs from first human administration to market. His career has spanned academic medicine (Professor of Clinical Pharmacology and Director of Innovation at The University of Adelaide) and pharmaceutical medicine. He has extensive expertise in the development of medicines as principal investigator in more than 750 early phase proof-of-concept, clinical pharmacology, drug interaction and special patient groups studies.

Professor Rolan's prior industry roles have included Medical Director of the U.K.'s largest phase 1 contract research organisation, Medeval, Chief Medical Officer for ASX listed biotech company, Bionomics Limited and Director of Drug Development for Singapore's first listed pharmaceutical company, iX Biopharma. Professor Rolan continues to advise on drug development for the international pharmaceutical industry, with a focus on the development of biomarkers, evaluation of novel therapies and mechanisms of disease, as well as conduct clinical practice in chronic pain management and headache.

Professor Rolan holds numerous academic and professional qualifications including a Bachelor of Medicine and Bachelor of Surgery (MBBS), and a Doctor of Medicine (MD). He also holds fellowships of the Royal Australian College of Physicians (FRACP), the Faculty of Pharmaceutical Medicine, Royal College of Physicians, (FFPM) and the Faculty of Pain Medicine, Australian and New Zealand College of Anaesthetists, (FFPMANZCA).

#### **Dr Steven Gourlay, Actinogen CEO and MD, commented:**

*“We are delighted to have Professor Paul Rolan join the Actinogen leadership team as Chief Medical Officer. Paul brings invaluable specialist skills to the CMO role that complement the current team and we look forward to his contribution to the advancement of our expanded Xanamem® clinical development pipeline. The Xanamem pipeline now includes a Phase 2 trial in Depression as well as trials investigating the treatment of people with early stage Alzheimer's Disease and Fragile X Syndrome.*

*“I look forward to working closely with Paul to help make a material difference to the quality of life for people and their families living with these serious neurological conditions.”*

**ENDS**

**Dr. Steven Gourlay**  
CEO & Managing Director  
P: +61 2 8964 7401  
E. [steven.gourlay@actinogen.com.au](mailto:steven.gourlay@actinogen.com.au)

**Investors**  
**Michael Roberts**  
Investor Relations  
M: +61 423 866 231  
E. [michael.roberts@actinogen.com.au](mailto:michael.roberts@actinogen.com.au)

**Media**  
**Randal Killip**  
Profile for Media  
M: +61 425 714 159  
E. [randal@profileformedia.com.au](mailto:randal@profileformedia.com.au)

***Announcement authorised by the Board of Directors of Actinogen Medical***

**About Actinogen Medical**

Actinogen Medical (ACW) is an ASX-listed, biotechnology company developing a novel therapy for neurological diseases associated with dysregulated brain cortisol. There is a strong association between cortisol and detrimental changes in the brain, affecting cognitive function, harm to brain cells and long-term cognitive health.

Cognitive function means how a person understands, remembers and thinks clearly. Cognitive functions include memory, reasoning, awareness and decision-making, and to a large extent, influence our personality.

We are currently developing our lead compound, Xanamem®, as a promising new therapy for Alzheimer's Disease, Fragile X Syndrome, Depression and other neurological diseases where reducing cortisol inside brain cells could have a positive impact. The cognitive dysfunction, behavioural abnormalities, and neuropsychological burden associated with these conditions is debilitating for patients, and there is a substantial unmet medical need for new and improved treatments.

**About Xanamem®**

Xanamem's novel mechanism of action works by blocking the production of intracellular cortisol through the inhibition of the 11β-HSD1 enzyme in the brain. Xanamem is designed to get into the brain after it is absorbed in the intestines upon swallowing its capsule.

Chronically elevated cortisol is associated with cognitive decline in Alzheimer's Disease, potentially linked to cognitive impairment and anxiety in Fragile X Syndrome, and cognitive impairment in Depression and other diseases.

The Company has studied 11β-HSD1 inhibition by Xanamem in more than 250 volunteers and patients, so far finding a statistically significant improvement in cognition over placebo in healthy, older volunteers. A series of Phase 2 studies in multiple diseases is being conducted to further confirm and characterise Xanamem's therapeutic potential.

Xanamem is an investigational product and is not approved for use outside of a clinical trial by the FDA or by any global regulatory authority. Xanamem® is a trademark of Actinogen Medical.

**Disclaimer**

This announcement and attachments may contain certain forward-looking statements that are based on subjective estimates and assumptions and relate to circumstances and events that have not taken place and may not take place. Such forward looking statements involve known and unknown risks, uncertainties, and other factors (such as significant business, economic and competitive uncertainties and contingencies, and regulatory and clinical development risks and uncertainties) which may cause the actual results or the performance of Actinogen Medical to be materially different from the results or performance expressed or implied by such forward looking statements. Past performance is not a reliable indicator of future performance. There can be no assurance that any forward-looking statements will be realised. Actinogen Medical does not make any representation or give any warranty as to the likelihood of achievement or reasonableness of any forward-looking statements.

**ACTINOGEN MEDICAL ENCOURAGES ALL CURRENT INVESTORS TO GO PAPERLESS BY REGISTERING THEIR DETAILS WITH THE DESIGNATED REGISTRY SERVICE PROVIDER, AUTOMIC GROUP.**